Profiling of the fecal microbiota and circulating microRNA-16 in IBS subjects with Blastocystis infection : a case–control study

Irritable bowel syndrome (IBS) is a prevalent gastrointestinal (GI) tract disorder. Although the main reason for IBS is not clear, the interaction between intestinal microorganisms and the gut barrier seems to play an important role in pathogenesis of IBS. The current study aimed to investigate the...

Full description

Saved in:
Bibliographic Details
Published inEuropean journal of medical research Vol. 28; no. 1; pp. 1 - 11
Main Authors Olyaiee, Alireza, Yadegar, Abbas, Mirsamadi, Elnaz Sadat, Sadeghi, Amir, Mirjalali, Hamed
Format Journal Article
LanguageEnglish
Published London BioMed Central Ltd 06.11.2023
BioMed Central
BMC
Subjects
Online AccessGet full text
ISSN2047-783X
0949-2321
2047-783X
DOI10.1186/s40001-023-01441-8

Cover

Loading…
Abstract Irritable bowel syndrome (IBS) is a prevalent gastrointestinal (GI) tract disorder. Although the main reason for IBS is not clear, the interaction between intestinal microorganisms and the gut barrier seems to play an important role in pathogenesis of IBS. The current study aimed to investigate the effect of Blastocystis on the gut microbiota profile and the circulation levels of microRNA (mir)-16 of IBS patients compared to healthy subjects. Stool and blood samples were collected from 80 participants including 40 samples from each IBS and healthy group. Upon DNA extraction from stool samples, barcoding region and quantitative real-time PCR were analyzed to investigate Blastocystis and the microbiota profile, respectively. RNA was extracted from serum samples of included subjects and the expression of mir-16 was evaluated using stem-loop protocol and qreal-time PCR. Significant changes between IBS patients and healthy controls was observed in Firmicutes , Actinobacteria , Faecalibacterium, and Alistipes . In IBS patients, the relative abundance of Bifidobacteria was directly correlated with the presence of Blastocystis , while Alistipes was decreased with Blastocystis . Lactobacillus was significantly increased in Blastocystis carriers. In healthy subjects, the relative abundance of Bifidobacteria was decreased, but Alistipes was increased in Blastocystis carriers. The changes in the Firmicutes/Bacteroidetes ratio was not significant in different groups. The relative expression of mir-16 in Blastocystis -negative IBS patients and healthy carriers was significantly overexpressed compared to control group. The presence of Blastocystis , decreased the relative expression of mir-16 in IBS patients compared to Blastocystis -negative IBS patients. The present study revealed that Blastocystis has the ability to change the abundance of some phyla/genera of bacteria in IBS and healthy subjects. Moreover, Blastocystis seems to  modulate the relative expression of microRNAs  to control the gut atmosphere, apply its pathogenicity, and provide a favor niche for its colonization.
AbstractList Abstract Irritable bowel syndrome (IBS) is a prevalent gastrointestinal (GI) tract disorder. Although the main reason for IBS is not clear, the interaction between intestinal microorganisms and the gut barrier seems to play an important role in pathogenesis of IBS. The current study aimed to investigate the effect of Blastocystis on the gut microbiota profile and the circulation levels of microRNA (mir)-16 of IBS patients compared to healthy subjects. Stool and blood samples were collected from 80 participants including 40 samples from each IBS and healthy group. Upon DNA extraction from stool samples, barcoding region and quantitative real-time PCR were analyzed to investigate Blastocystis and the microbiota profile, respectively. RNA was extracted from serum samples of included subjects and the expression of mir-16 was evaluated using stem-loop protocol and qreal-time PCR. Significant changes between IBS patients and healthy controls was observed in Firmicutes, Actinobacteria, Faecalibacterium, and Alistipes. In IBS patients, the relative abundance of Bifidobacteria was directly correlated with the presence of Blastocystis, while Alistipes was decreased with Blastocystis. Lactobacillus was significantly increased in Blastocystis carriers. In healthy subjects, the relative abundance of Bifidobacteria was decreased, but Alistipes was increased in Blastocystis carriers. The changes in the Firmicutes/Bacteroidetes ratio was not significant in different groups. The relative expression of mir-16 in Blastocystis-negative IBS patients and healthy carriers was significantly overexpressed compared to control group. The presence of Blastocystis, decreased the relative expression of mir-16 in IBS patients compared to Blastocystis-negative IBS patients. The present study revealed that Blastocystis has the ability to change the abundance of some phyla/genera of bacteria in IBS and healthy subjects. Moreover, Blastocystis seems to  modulate the relative expression of microRNAs  to control the gut atmosphere, apply its pathogenicity, and provide a favor niche for its colonization.
Irritable bowel syndrome (IBS) is a prevalent gastrointestinal (GI) tract disorder. Although the main reason for IBS is not clear, the interaction between intestinal microorganisms and the gut barrier seems to play an important role in pathogenesis of IBS. The current study aimed to investigate the effect of Blastocystis on the gut microbiota profile and the circulation levels of microRNA (mir)-16 of IBS patients compared to healthy subjects. Stool and blood samples were collected from 80 participants including 40 samples from each IBS and healthy group. Upon DNA extraction from stool samples, barcoding region and quantitative real-time PCR were analyzed to investigate Blastocystis and the microbiota profile, respectively. RNA was extracted from serum samples of included subjects and the expression of mir-16 was evaluated using stem-loop protocol and qreal-time PCR. Significant changes between IBS patients and healthy controls was observed in Firmicutes, Actinobacteria, Faecalibacterium, and Alistipes. In IBS patients, the relative abundance of Bifidobacteria was directly correlated with the presence of Blastocystis, while Alistipes was decreased with Blastocystis. Lactobacillus was significantly increased in Blastocystis carriers. In healthy subjects, the relative abundance of Bifidobacteria was decreased, but Alistipes was increased in Blastocystis carriers. The changes in the Firmicutes/Bacteroidetes ratio was not significant in different groups. The relative expression of mir-16 in Blastocystis-negative IBS patients and healthy carriers was significantly overexpressed compared to control group. The presence of Blastocystis, decreased the relative expression of mir-16 in IBS patients compared to Blastocystis-negative IBS patients. The present study revealed that Blastocystis has the ability to change the abundance of some phyla/genera of bacteria in IBS and healthy subjects. Moreover, Blastocystis seems to modulate the relative expression of microRNAs to control the gut atmosphere, apply its pathogenicity, and provide a favor niche for its colonization.
Irritable bowel syndrome (IBS) is a prevalent gastrointestinal (GI) tract disorder. Although the main reason for IBS is not clear, the interaction between intestinal microorganisms and the gut barrier seems to play an important role in pathogenesis of IBS. The current study aimed to investigate the effect of Blastocystis on the gut microbiota profile and the circulation levels of microRNA (mir)-16 of IBS patients compared to healthy subjects. Stool and blood samples were collected from 80 participants including 40 samples from each IBS and healthy group. Upon DNA extraction from stool samples, barcoding region and quantitative real-time PCR were analyzed to investigate Blastocystis and the microbiota profile, respectively. RNA was extracted from serum samples of included subjects and the expression of mir-16 was evaluated using stem-loop protocol and qreal-time PCR. Significant changes between IBS patients and healthy controls was observed in Firmicutes, Actinobacteria, Faecalibacterium, and Alistipes. In IBS patients, the relative abundance of Bifidobacteria was directly correlated with the presence of Blastocystis, while Alistipes was decreased with Blastocystis. Lactobacillus was significantly increased in Blastocystis carriers. In healthy subjects, the relative abundance of Bifidobacteria was decreased, but Alistipes was increased in Blastocystis carriers. The changes in the Firmicutes/Bacteroidetes ratio was not significant in different groups. The relative expression of mir-16 in Blastocystis-negative IBS patients and healthy carriers was significantly overexpressed compared to control group. The presence of Blastocystis, decreased the relative expression of mir-16 in IBS patients compared to Blastocystis-negative IBS patients. The present study revealed that Blastocystis has the ability to change the abundance of some phyla/genera of bacteria in IBS and healthy subjects. Moreover, Blastocystisseems to modulate the relative expression of microRNAs to control the gut atmosphere, apply its pathogenicity, and provide a favor niche for its colonization.
Irritable bowel syndrome (IBS) is a prevalent gastrointestinal (GI) tract disorder. Although the main reason for IBS is not clear, the interaction between intestinal microorganisms and the gut barrier seems to play an important role in pathogenesis of IBS. The current study aimed to investigate the effect of Blastocystis on the gut microbiota profile and the circulation levels of microRNA (mir)-16 of IBS patients compared to healthy subjects. Stool and blood samples were collected from 80 participants including 40 samples from each IBS and healthy group. Upon DNA extraction from stool samples, barcoding region and quantitative real-time PCR were analyzed to investigate Blastocystis and the microbiota profile, respectively. RNA was extracted from serum samples of included subjects and the expression of mir-16 was evaluated using stem-loop protocol and qreal-time PCR. Significant changes between IBS patients and healthy controls was observed in Firmicutes , Actinobacteria , Faecalibacterium, and Alistipes . In IBS patients, the relative abundance of Bifidobacteria was directly correlated with the presence of Blastocystis , while Alistipes was decreased with Blastocystis . Lactobacillus was significantly increased in Blastocystis carriers. In healthy subjects, the relative abundance of Bifidobacteria was decreased, but Alistipes was increased in Blastocystis carriers. The changes in the Firmicutes/Bacteroidetes ratio was not significant in different groups. The relative expression of mir-16 in Blastocystis -negative IBS patients and healthy carriers was significantly overexpressed compared to control group. The presence of Blastocystis , decreased the relative expression of mir-16 in IBS patients compared to Blastocystis -negative IBS patients. The present study revealed that Blastocystis has the ability to change the abundance of some phyla/genera of bacteria in IBS and healthy subjects. Moreover, Blastocystis seems to  modulate the relative expression of microRNAs  to control the gut atmosphere, apply its pathogenicity, and provide a favor niche for its colonization.
Irritable bowel syndrome (IBS) is a prevalent gastrointestinal (GI) tract disorder. Although the main reason for IBS is not clear, the interaction between intestinal microorganisms and the gut barrier seems to play an important role in pathogenesis of IBS. The current study aimed to investigate the effect of Blastocystis on the gut microbiota profile and the circulation levels of microRNA (mir)-16 of IBS patients compared to healthy subjects. Stool and blood samples were collected from 80 participants including 40 samples from each IBS and healthy group. Upon DNA extraction from stool samples, barcoding region and quantitative real-time PCR were analyzed to investigate Blastocystis and the microbiota profile, respectively. RNA was extracted from serum samples of included subjects and the expression of mir-16 was evaluated using stem-loop protocol and qreal-time PCR. Significant changes between IBS patients and healthy controls was observed in Firmicutes, Actinobacteria, Faecalibacterium, and Alistipes. In IBS patients, the relative abundance of Bifidobacteria was directly correlated with the presence of Blastocystis, while Alistipes was decreased with Blastocystis. Lactobacillus was significantly increased in Blastocystis carriers. In healthy subjects, the relative abundance of Bifidobacteria was decreased, but Alistipes was increased in Blastocystis carriers. The changes in the Firmicutes/Bacteroidetes ratio was not significant in different groups. The relative expression of mir-16 in Blastocystis-negative IBS patients and healthy carriers was significantly overexpressed compared to control group. The presence of Blastocystis, decreased the relative expression of mir-16 in IBS patients compared to Blastocystis-negative IBS patients. The present study revealed that Blastocystis has the ability to change the abundance of some phyla/genera of bacteria in IBS and healthy subjects. Moreover, Blastocystis seems to modulate the relative expression of microRNAs to control the gut atmosphere, apply its pathogenicity, and provide a favor niche for its colonization. Keywords: IBS, Blastocystis, Fecal microbiota, MicroRNA, mir-16
Irritable bowel syndrome (IBS) is a prevalent gastrointestinal (GI) tract disorder. Although the main reason for IBS is not clear, the interaction between intestinal microorganisms and the gut barrier seems to play an important role in pathogenesis of IBS. The current study aimed to investigate the effect of Blastocystis on the gut microbiota profile and the circulation levels of microRNA (mir)-16 of IBS patients compared to healthy subjects. Stool and blood samples were collected from 80 participants including 40 samples from each IBS and healthy group. Upon DNA extraction from stool samples, barcoding region and quantitative real-time PCR were analyzed to investigate Blastocystis and the microbiota profile, respectively. RNA was extracted from serum samples of included subjects and the expression of mir-16 was evaluated using stem-loop protocol and qreal-time PCR. Significant changes between IBS patients and healthy controls was observed in Firmicutes, Actinobacteria, Faecalibacterium, and Alistipes. In IBS patients, the relative abundance of Bifidobacteria was directly correlated with the presence of Blastocystis, while Alistipes was decreased with Blastocystis. Lactobacillus was significantly increased in Blastocystis carriers. In healthy subjects, the relative abundance of Bifidobacteria was decreased, but Alistipes was increased in Blastocystis carriers. The changes in the Firmicutes/Bacteroidetes ratio was not significant in different groups. The relative expression of mir-16 in Blastocystis-negative IBS patients and healthy carriers was significantly overexpressed compared to control group. The presence of Blastocystis, decreased the relative expression of mir-16 in IBS patients compared to Blastocystis-negative IBS patients. The present study revealed that Blastocystis has the ability to change the abundance of some phyla/genera of bacteria in IBS and healthy subjects. Moreover, Blastocystis seems to modulate the relative expression of microRNAs to control the gut atmosphere, apply its pathogenicity, and provide a favor niche for its colonization.Irritable bowel syndrome (IBS) is a prevalent gastrointestinal (GI) tract disorder. Although the main reason for IBS is not clear, the interaction between intestinal microorganisms and the gut barrier seems to play an important role in pathogenesis of IBS. The current study aimed to investigate the effect of Blastocystis on the gut microbiota profile and the circulation levels of microRNA (mir)-16 of IBS patients compared to healthy subjects. Stool and blood samples were collected from 80 participants including 40 samples from each IBS and healthy group. Upon DNA extraction from stool samples, barcoding region and quantitative real-time PCR were analyzed to investigate Blastocystis and the microbiota profile, respectively. RNA was extracted from serum samples of included subjects and the expression of mir-16 was evaluated using stem-loop protocol and qreal-time PCR. Significant changes between IBS patients and healthy controls was observed in Firmicutes, Actinobacteria, Faecalibacterium, and Alistipes. In IBS patients, the relative abundance of Bifidobacteria was directly correlated with the presence of Blastocystis, while Alistipes was decreased with Blastocystis. Lactobacillus was significantly increased in Blastocystis carriers. In healthy subjects, the relative abundance of Bifidobacteria was decreased, but Alistipes was increased in Blastocystis carriers. The changes in the Firmicutes/Bacteroidetes ratio was not significant in different groups. The relative expression of mir-16 in Blastocystis-negative IBS patients and healthy carriers was significantly overexpressed compared to control group. The presence of Blastocystis, decreased the relative expression of mir-16 in IBS patients compared to Blastocystis-negative IBS patients. The present study revealed that Blastocystis has the ability to change the abundance of some phyla/genera of bacteria in IBS and healthy subjects. Moreover, Blastocystis seems to modulate the relative expression of microRNAs to control the gut atmosphere, apply its pathogenicity, and provide a favor niche for its colonization.
ArticleNumber 483
Audience Academic
Author Sadeghi, Amir
Mirsamadi, Elnaz Sadat
Olyaiee, Alireza
Mirjalali, Hamed
Yadegar, Abbas
Author_xml – sequence: 1
  givenname: Alireza
  surname: Olyaiee
  fullname: Olyaiee, Alireza
– sequence: 2
  givenname: Abbas
  surname: Yadegar
  fullname: Yadegar, Abbas
– sequence: 3
  givenname: Elnaz Sadat
  surname: Mirsamadi
  fullname: Mirsamadi, Elnaz Sadat
– sequence: 4
  givenname: Amir
  surname: Sadeghi
  fullname: Sadeghi, Amir
– sequence: 5
  givenname: Hamed
  surname: Mirjalali
  fullname: Mirjalali, Hamed
BookMark eNp9ks2KFDEQxxtZwXXdF_AUEMRLr0lPOp32IruLHwOLih_gLVSnq2cyZDprJ63MTfARfAGfxUfxSayeWXFnEckhIfnVv1JV_7vZQR96zLL7gp8IodXjKDnnIufFLOdCSpHrW9lhwWWVV3r28eDa-U52HOOKaK4KVdX1YfbtzRA6512_YKFjaYmsQwuerZ0dQuNCAgZ9y6wb7OghTdz26e2r01wo5no2P3vH4tis0KbIvri0ZGceYgp2E5OLRJBgcqH_-eMJA2Yh4q-v323o0xA8i2lsN_ey2x34iMdX-1H24fmz9-cv84vXL-bnpxe5Lasi5dbOZNmWVqqilLVC2iy0ba0VFhoKXopC1C1YXraai7KbVaLjumyxbgAt6tlRNt_ptgFW5nJwaxg2JoAz24swLAwMyVmPRogGu6pTgAqk1Y0uSz2ThVSNQCF5Q1pPd1qXY7PG1iLVA35PdP-ld0uzCJ-N2LZeKlJ4dKUwhE8jxmTWLlr0HnoMYzSF1qqmyVac0Ac30FUYh556RVTNSbKq9F9qAVQB9T1QYjuJmtOqElpOKFEn_6BotUiDJWORG3A_4OG1gCWCT8sY_DjNNO6DegeSPWIcsDPWJZgwyuA8VW4mu5qdXQ3Z1WztaqavFzdC_zTyP0G_AXNf738
CitedBy_id crossref_primary_10_1007_s10238_024_01396_y
crossref_primary_10_3390_ijms26010413
crossref_primary_10_3389_fmicb_2025_1540943
Cites_doi 10.1186/s12967-023-03953-7
10.1042/BCJ20160510
10.1016/j.mce.2022.111572
10.1111/1462-2920.14271
10.1186/s40168-016-0191-0
10.1097/MD.0000000000014513
10.7150/thno.81583
10.3389/fmed.2022.940332
10.1186/s40168-015-0139-9
10.1371/journal.ppat.1009253
10.1016/j.semcdb.2023.01.009
10.1053/j.gastro.2016.09.049
10.3390/jcm8111808
10.1186/s40168-019-0704-8
10.3390/microorganisms10020326
10.1128/Spectrum.00484-21
10.1186/1471-2164-14-788
10.3389/fmicb.2023.1147945
10.1016/j.mimet.2011.06.010
10.5009/gnl19379
10.1007/s00436-012-2830-0
10.1128/AEM.05605-11
10.3906/sag-2002-57
10.5217/ir.2015.13.1.11
10.3389/fmicb.2018.01600
10.1371/journal.pone.0015484
10.7150/ijbs.45885
10.1016/j.jbc.2022.102461
10.3390/jpm11010035
10.1038/s41575-019-0157-3
10.1186/s12876-021-01693-w
10.1186/s12866-022-02528-8
10.3389/fimmu.2020.00906
10.1053/j.gastro.2011.07.043
10.1007/s00018-022-04271-9
10.1186/s12866-021-02341-9
10.1172/JCI130976
10.1038/s41591-020-01183-8
10.3389/fmed.2022.890127
10.2166/wh.2021.011
10.3390/microorganisms10010034
10.3920/BM2012.0018
10.1152/ajpgi.00154.2011
10.5056/jnm22093
10.1186/s13071-015-1069-x
10.1159/000477205
10.1111/j.1462-5822.2012.01814.x
10.3390/nu12041096
10.1016/j.ebiom.2019.11.023
10.1136/gutjnl-2016-311477
10.3390/toxins13110758
10.1128/mSystems.00007-18
10.1038/ismej.2017.139
10.1016/j.mehy.2018.04.006
10.1038/s41396-022-01262-3
ContentType Journal Article
Copyright COPYRIGHT 2023 BioMed Central Ltd.
2023. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
2023. The Author(s).
The Author(s) 2023
Copyright_xml – notice: COPYRIGHT 2023 BioMed Central Ltd.
– notice: 2023. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
– notice: 2023. The Author(s).
– notice: The Author(s) 2023
DBID AAYXX
CITATION
3V.
7X7
7XB
88E
8FI
8FJ
8FK
ABUWG
AFKRA
AZQEC
BENPR
CCPQU
DWQXO
FYUFA
GHDGH
K9.
M0S
M1P
PHGZM
PHGZT
PIMPY
PJZUB
PKEHL
PPXIY
PQEST
PQQKQ
PQUKI
7X8
5PM
DOA
DOI 10.1186/s40001-023-01441-8
DatabaseName CrossRef
ProQuest Central (Corporate)
Proquest Health & Medical Complete
ProQuest Central (purchase pre-March 2016)
Medical Database (Alumni Edition)
Hospital Premium Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Central
ProQuest Central UK/Ireland
ProQuest Central Essentials
ProQuest Central
ProQuest One
ProQuest Central
Health Research Premium Collection
Health Research Premium Collection (Alumni)
ProQuest Health & Medical Complete (Alumni)
ProQuest Health & Medical Collection
Medical Database
ProQuest Central Premium
ProQuest One Academic (New)
ProQuest Publicly Available Content Database
ProQuest Health & Medical Research Collection
ProQuest One Academic Middle East (New)
ProQuest One Health & Nursing
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Academic
ProQuest One Academic UKI Edition
MEDLINE - Academic
PubMed Central (Full Participant titles)
DOAJ Directory of Open Access Journals
DatabaseTitle CrossRef
Publicly Available Content Database
ProQuest One Academic Middle East (New)
ProQuest Central Essentials
ProQuest One Academic Eastern Edition
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
ProQuest One Community College
ProQuest One Health & Nursing
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
ProQuest Hospital Collection (Alumni)
ProQuest Central
ProQuest Health & Medical Complete
Health Research Premium Collection
ProQuest Medical Library
ProQuest One Academic UKI Edition
Health and Medicine Complete (Alumni Edition)
ProQuest Central Korea
Health & Medical Research Collection
ProQuest Central (New)
ProQuest One Academic
ProQuest One Academic (New)
ProQuest Medical Library (Alumni)
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList

Publicly Available Content Database



MEDLINE - Academic
CrossRef
Database_xml – sequence: 1
  dbid: DOA
  name: DOAJ (Directory of Open Access Journals)
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 2
  dbid: BENPR
  name: ProQuest Central
  url: https://www.proquest.com/central
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 2047-783X
EndPage 11
ExternalDocumentID oai_doaj_org_article_11bef7f6ae6a4c8b855834246b1e140b
PMC10626746
A771848901
10_1186_s40001_023_01441_8
GeographicLocations Iran
Germany
GeographicLocations_xml – name: Iran
– name: Germany
GroupedDBID ---
0R~
4.4
53G
5GY
5VS
7X7
88E
8FI
8FJ
AAFWJ
AAJSJ
AASML
AAYXX
ABUWG
ACGFS
ADBBV
ADRAZ
ADUKV
AENEX
AFKRA
AFPKN
AHBYD
AHMBA
AHYZX
ALIPV
ALMA_UNASSIGNED_HOLDINGS
AMKLP
AOIJS
BAWUL
BCNDV
BENPR
BFQNJ
BMC
BPHCQ
BVXVI
C6C
CCPQU
CITATION
DIK
EBD
EBLON
EBS
EMOBN
F5P
FYUFA
GROUPED_DOAJ
HMCUK
HYE
IAO
IHR
IHW
INH
INR
ITC
KQ8
M1P
M48
OK1
P2P
PGMZT
PHGZM
PHGZT
PIMPY
PQQKQ
PROAC
PSQYO
RBZ
RNS
ROL
RPM
RSV
SMD
SOJ
SV3
UKHRP
PMFND
3V.
7XB
8FK
AZQEC
DWQXO
K9.
PJZUB
PKEHL
PPXIY
PQEST
PQUKI
7X8
5PM
PUEGO
ID FETCH-LOGICAL-c572t-cc345d5c4625496e625cadd986e28a2051219dac05d8015f371f085de9baece83
IEDL.DBID M48
ISSN 2047-783X
0949-2321
IngestDate Wed Aug 27 00:47:14 EDT 2025
Thu Aug 21 18:36:13 EDT 2025
Fri Jul 11 10:41:09 EDT 2025
Sat Jul 26 02:33:46 EDT 2025
Tue Jun 17 22:23:17 EDT 2025
Tue Jun 10 21:17:14 EDT 2025
Thu May 22 21:20:02 EDT 2025
Thu Apr 24 22:56:06 EDT 2025
Tue Jul 01 02:25:18 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 1
Language English
License Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c572t-cc345d5c4625496e625cadd986e28a2051219dac05d8015f371f085de9baece83
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
OpenAccessLink http://journals.scholarsportal.info/openUrl.xqy?doi=10.1186/s40001-023-01441-8
PQID 2890106778
PQPubID 2040181
PageCount 11
ParticipantIDs doaj_primary_oai_doaj_org_article_11bef7f6ae6a4c8b855834246b1e140b
pubmedcentral_primary_oai_pubmedcentral_nih_gov_10626746
proquest_miscellaneous_2886940070
proquest_journals_2890106778
gale_infotracmisc_A771848901
gale_infotracacademiconefile_A771848901
gale_healthsolutions_A771848901
crossref_citationtrail_10_1186_s40001_023_01441_8
crossref_primary_10_1186_s40001_023_01441_8
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2023-11-06
PublicationDateYYYYMMDD 2023-11-06
PublicationDate_xml – month: 11
  year: 2023
  text: 2023-11-06
  day: 06
PublicationDecade 2020
PublicationPlace London
PublicationPlace_xml – name: London
PublicationTitle European journal of medical research
PublicationYear 2023
Publisher BioMed Central Ltd
BioMed Central
BMC
Publisher_xml – name: BioMed Central Ltd
– name: BioMed Central
– name: BMC
References LR Lopetuso (1441_CR43) 2018; 36
M Norouzi (1441_CR22) 2022; 9
I-K Wang (1441_CR30) 2012; 78
Q Sun (1441_CR50) 2019; 98
L Deng (1441_CR53) 2023; 13
C Martínez (1441_CR21) 2017; 66
V Shankar (1441_CR9) 2015; 3
S Cifre (1441_CR13) 2018; 116
F Asnicar (1441_CR16) 2021; 27
L Mei (1441_CR2) 2021; 21
A Gasbarrini (1441_CR7) 2008; 12
M Rajilić-Stojanović (1441_CR8) 2011; 141
S Nemati (1441_CR12) 2021; 19
M Moszak (1441_CR25) 2020; 12
LK Vigsnæs (1441_CR32) 2012; 3
BJ Parker (1441_CR46) 2020; 11
SH Lee (1441_CR57) 2015; 13
F Beghini (1441_CR15) 2017; 11
N Springham (1441_CR28) 2015; 4
MJ Kozieł (1441_CR58) 2021; 13
MH Ismail (1441_CR39) 2022; 68
PH Johnsen (1441_CR3) 2020; 51
SM Lee (1441_CR42) 2021; 15
G Gargari (1441_CR51) 2018; 20
L Zhao (1441_CR6) 2020; 130
L Deng (1441_CR35) 2021; 17
IM Carroll (1441_CR45) 2011; 301
F Dogruman-Al (1441_CR14) 2010; 5
ML Hermann-Bank (1441_CR27) 2013; 14
I Schoultz (1441_CR56) 1909; 2020
S Fagoonee (1441_CR10) 2019; 8
B Dalile (1441_CR52) 2019; 16
K Oliphant (1441_CR48) 2019; 7
TB De Gregoris (1441_CR24) 2011; 86
H Mirza (1441_CR18) 2012; 14
H Mohammad Rahimi (1441_CR19) 2022; 22
S Keshavarz Azizi Raftar (1441_CR29) 2021; 9
W Jiang (1441_CR49) 2022; 28
ZA Barandouzi (1441_CR44) 2021; 11
A Olivo-Diaz (1441_CR38) 2012; 111
EM Quigley (1441_CR31) 2013; 9
H Chen (1441_CR41) 2023; 21
KJ O'Riordan (1441_CR47) 2022; 546
E Thursby (1441_CR26) 2017; 474
MJ Kim (1441_CR36) 2021; 10
X Zhuang (1441_CR34) 2018; 9
R Nagel (1441_CR4) 2016; 4
M Xi (1441_CR60) 2022; 298
R Nagel (1441_CR40) 2015; 8
A Olyaiee (1441_CR1) 2022; 9
CR Stensvold (1441_CR37) 2022; 10
FS Gholam-Mostafaei (1441_CR23) 2023; 14
M Nieves-Ramírez (1441_CR11) 2018; 3
J Tap (1441_CR33) 2017; 152
J Mayneris-Perxachs (1441_CR55) 2022; 16
L Deng (1441_CR54) 2022; 79
X Zhao (1441_CR59) 2021; 17
HF Dale (1441_CR5) 2020; 50
1441_CR20
SA Karamati (1441_CR17) 2021; 21
References_xml – volume: 21
  start-page: 117
  year: 2023
  ident: 1441_CR41
  publication-title: J Transl Med
  doi: 10.1186/s12967-023-03953-7
– volume: 474
  start-page: 1823
  year: 2017
  ident: 1441_CR26
  publication-title: Biochem J
  doi: 10.1042/BCJ20160510
– volume: 546
  year: 2022
  ident: 1441_CR47
  publication-title: Mol Cell Endocrinol
  doi: 10.1016/j.mce.2022.111572
– volume: 20
  start-page: 3201
  year: 2018
  ident: 1441_CR51
  publication-title: Environ Microbiol
  doi: 10.1111/1462-2920.14271
– volume: 4
  start-page: 47
  year: 2016
  ident: 1441_CR4
  publication-title: Microbiome
  doi: 10.1186/s40168-016-0191-0
– volume: 98
  year: 2019
  ident: 1441_CR50
  publication-title: Medicine (Baltimore)
  doi: 10.1097/MD.0000000000014513
– volume: 13
  start-page: 1165
  year: 2023
  ident: 1441_CR53
  publication-title: Theranostics
  doi: 10.7150/thno.81583
– volume: 9
  year: 2022
  ident: 1441_CR22
  publication-title: Front Med (Lausanne)
  doi: 10.3389/fmed.2022.940332
– volume: 3
  start-page: 73
  year: 2015
  ident: 1441_CR9
  publication-title: Microbiome
  doi: 10.1186/s40168-015-0139-9
– volume: 17
  year: 2021
  ident: 1441_CR35
  publication-title: PLoS Pathog
  doi: 10.1371/journal.ppat.1009253
– ident: 1441_CR20
  doi: 10.1016/j.semcdb.2023.01.009
– volume: 152
  start-page: 111
  year: 2017
  ident: 1441_CR33
  publication-title: Gastroenterology
  doi: 10.1053/j.gastro.2016.09.049
– volume: 8
  start-page: 1808
  year: 2019
  ident: 1441_CR10
  publication-title: J Clin Med
  doi: 10.3390/jcm8111808
– volume: 7
  start-page: 91
  year: 2019
  ident: 1441_CR48
  publication-title: Microbiome
  doi: 10.1186/s40168-019-0704-8
– volume: 10
  start-page: 326
  year: 2022
  ident: 1441_CR37
  publication-title: Microorganisms
  doi: 10.3390/microorganisms10020326
– volume: 9
  start-page: e00484
  year: 2021
  ident: 1441_CR29
  publication-title: Microbiol Spect
  doi: 10.1128/Spectrum.00484-21
– volume: 4
  issue: u209153
  year: 2015
  ident: 1441_CR28
  publication-title: BMJ Open Qual
– volume: 14
  start-page: 1
  year: 2013
  ident: 1441_CR27
  publication-title: BMC Genomic
  doi: 10.1186/1471-2164-14-788
– volume: 14
  start-page: 499
  year: 2023
  ident: 1441_CR23
  publication-title: Front Microbiol
  doi: 10.3389/fmicb.2023.1147945
– volume: 86
  start-page: 351
  year: 2011
  ident: 1441_CR24
  publication-title: J Microbiol Method
  doi: 10.1016/j.mimet.2011.06.010
– volume: 15
  start-page: 253
  year: 2021
  ident: 1441_CR42
  publication-title: Gut Liver
  doi: 10.5009/gnl19379
– volume: 111
  start-page: 487
  year: 2012
  ident: 1441_CR38
  publication-title: Parasitol Res
  doi: 10.1007/s00436-012-2830-0
– volume: 78
  start-page: 1107
  year: 2012
  ident: 1441_CR30
  publication-title: Appl Environ Microbiol
  doi: 10.1128/AEM.05605-11
– volume: 50
  start-page: 1632
  year: 2020
  ident: 1441_CR5
  publication-title: Turk J Med Sci
  doi: 10.3906/sag-2002-57
– volume: 13
  start-page: 11
  year: 2015
  ident: 1441_CR57
  publication-title: Intestin Res
  doi: 10.5217/ir.2015.13.1.11
– volume: 9
  start-page: 1600
  year: 2018
  ident: 1441_CR34
  publication-title: Front Microbiol
  doi: 10.3389/fmicb.2018.01600
– volume: 5
  year: 2010
  ident: 1441_CR14
  publication-title: Turkey PLoS One
  doi: 10.1371/journal.pone.0015484
– volume: 2020
  start-page: 9
  year: 1909
  ident: 1441_CR56
  publication-title: Cells
– volume: 17
  start-page: 712
  year: 2021
  ident: 1441_CR59
  publication-title: Int J Biol Sci
  doi: 10.7150/ijbs.45885
– volume: 298
  issue: 11
  year: 2022
  ident: 1441_CR60
  publication-title: J Biol Chem
  doi: 10.1016/j.jbc.2022.102461
– volume: 11
  start-page: 35
  year: 2021
  ident: 1441_CR44
  publication-title: J Pers Med
  doi: 10.3390/jpm11010035
– volume: 16
  start-page: 461
  year: 2019
  ident: 1441_CR52
  publication-title: Nat Rev Gastroenterol Hepatol
  doi: 10.1038/s41575-019-0157-3
– volume: 21
  start-page: 105
  year: 2021
  ident: 1441_CR2
  publication-title: BMC Gastroenterol
  doi: 10.1186/s12876-021-01693-w
– volume: 22
  start-page: 111
  year: 2022
  ident: 1441_CR19
  publication-title: BMC Microbiol
  doi: 10.1186/s12866-022-02528-8
– volume: 11
  start-page: 906
  year: 2020
  ident: 1441_CR46
  publication-title: Front Immunol
  doi: 10.3389/fimmu.2020.00906
– volume: 141
  start-page: 1792
  year: 2011
  ident: 1441_CR8
  publication-title: Gastroenterology
  doi: 10.1053/j.gastro.2011.07.043
– volume: 79
  start-page: 245
  year: 2022
  ident: 1441_CR54
  publication-title: Cell Mol Life Sci
  doi: 10.1007/s00018-022-04271-9
– volume: 21
  start-page: 285
  year: 2021
  ident: 1441_CR17
  publication-title: BMC Microbiol
  doi: 10.1186/s12866-021-02341-9
– volume: 130
  start-page: 438
  year: 2020
  ident: 1441_CR6
  publication-title: J Clin Invest
  doi: 10.1172/JCI130976
– volume: 27
  start-page: 321
  year: 2021
  ident: 1441_CR16
  publication-title: Nat Med
  doi: 10.1038/s41591-020-01183-8
– volume: 9
  year: 2022
  ident: 1441_CR1
  publication-title: Front Med (Lausanne)
  doi: 10.3389/fmed.2022.890127
– volume: 19
  start-page: 687
  year: 2021
  ident: 1441_CR12
  publication-title: J Water Health
  doi: 10.2166/wh.2021.011
– volume: 10
  start-page: 34
  year: 2021
  ident: 1441_CR36
  publication-title: Microorganisms
  doi: 10.3390/microorganisms10010034
– volume: 3
  start-page: 287
  year: 2012
  ident: 1441_CR32
  publication-title: Beneficial Microb
  doi: 10.3920/BM2012.0018
– volume: 301
  start-page: G799
  year: 2011
  ident: 1441_CR45
  publication-title: Am J Physiol Gastrointest Liver Physiol
  doi: 10.1152/ajpgi.00154.2011
– volume: 28
  start-page: 540
  year: 2022
  ident: 1441_CR49
  publication-title: J Neurogastroenterol Motil
  doi: 10.5056/jnm22093
– volume: 8
  start-page: 453
  year: 2015
  ident: 1441_CR40
  publication-title: Parasit Vectors
  doi: 10.1186/s13071-015-1069-x
– volume: 36
  start-page: 56
  year: 2018
  ident: 1441_CR43
  publication-title: Dig Dis
  doi: 10.1159/000477205
– volume: 14
  start-page: 1474
  year: 2012
  ident: 1441_CR18
  publication-title: Cell Microbiol
  doi: 10.1111/j.1462-5822.2012.01814.x
– volume: 12
  start-page: 1096
  year: 2020
  ident: 1441_CR25
  publication-title: Nutrients
  doi: 10.3390/nu12041096
– volume: 51
  year: 2020
  ident: 1441_CR3
  publication-title: EBioMedicine
  doi: 10.1016/j.ebiom.2019.11.023
– volume: 66
  start-page: 1537
  year: 2017
  ident: 1441_CR21
  publication-title: Gut
  doi: 10.1136/gutjnl-2016-311477
– volume: 13
  start-page: 758
  year: 2021
  ident: 1441_CR58
  publication-title: Toxins
  doi: 10.3390/toxins13110758
– volume: 3
  start-page: e00007
  year: 2018
  ident: 1441_CR11
  publication-title: Msystems
  doi: 10.1128/mSystems.00007-18
– volume: 11
  start-page: 2848
  year: 2017
  ident: 1441_CR15
  publication-title: ISME J
  doi: 10.1038/ismej.2017.139
– volume: 116
  start-page: 4
  year: 2018
  ident: 1441_CR13
  publication-title: Med Hypotheses
  doi: 10.1016/j.mehy.2018.04.006
– volume: 9
  start-page: 560
  year: 2013
  ident: 1441_CR31
  publication-title: Gastroenterol Hepatol
– volume: 68
  start-page: 77
  year: 2022
  ident: 1441_CR39
  publication-title: Ann Parasitol
– volume: 12
  start-page: 111
  issue: Suppl 1
  year: 2008
  ident: 1441_CR7
  publication-title: Eur Rev Med Pharmacol Sci
– volume: 16
  start-page: 2181
  year: 2022
  ident: 1441_CR55
  publication-title: Isme J
  doi: 10.1038/s41396-022-01262-3
SSID ssj0000626799
Score 2.3557289
Snippet Irritable bowel syndrome (IBS) is a prevalent gastrointestinal (GI) tract disorder. Although the main reason for IBS is not clear, the interaction between...
Abstract Irritable bowel syndrome (IBS) is a prevalent gastrointestinal (GI) tract disorder. Although the main reason for IBS is not clear, the interaction...
SourceID doaj
pubmedcentral
proquest
gale
crossref
SourceType Open Website
Open Access Repository
Aggregation Database
Enrichment Source
Index Database
StartPage 1
SubjectTerms Bacteria
Blastocystis
Consent
Digestive system
Fecal microbiota
Gastroenterology
Guardians
Health aspects
IBS
Irritable bowel syndrome
Medical research
Medicine, Experimental
Microbiota
Microbiota (Symbiotic organisms)
Microorganisms
MicroRNA
MicroRNAs
mir-16
Proteins
SummonAdditionalLinks – databaseName: DOAJ Directory of Open Access Journals
  dbid: DOA
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3NatVAFB6ki-JGtCpGax1BcCGh-ZmZnLi7VyxVaBG10N0wf8ELmitN7sJdoY_gC_gsPopP0nMmuZcbBd24CmROIHP-Z-bMdxh7FmwNtlQibarKpQJ8SK0DldYqlBhSDITYee7kVB2fibfn8nyr1RfVhA3wwAPjDvPchqZqlAnKCAcWpIRSFELZPODiwJL3xZi3tZgafHChqrpe35IBddiJLFYPFVQ-hDlACpNIFAH7_3TLv5dKbsWeo9vs1pg08tnws3fYjdDusd2T8Vj8Lrt6FztvYxTiy4ZjSsebgLznXxYDzFJvuGk9d4sLF7t1IV0cen86S3PFFy1_M__Au5WlTZmO094sn2Na3S_dN3QBHV-XbLU_f7zkhjsMfb8uv49l7jxC1N5jZ0evP746TsfuCqmTVdGnzpVCeumEojWiCvhw6OxqUKEAU6CxojPzxmXSYxSTTVnlDeZnPtTWBBegvM922mUbHjDuc2GkCxnUGQgvvRWegMAolWmKAnzC8jWntRuhx6kDxmcdlyCg9CAdjdLRUToaEvZi883XAXjjr9RzEuCGkkCz4wtUJT2qkv6XKiXsCYlfDzdQN6avZxUGcIGTyxP2PFKQ8eMEnBnvMCAbCEZrQrk_oUSjddPhtYrp0Wl0ms58B0S_hD3dDNOXVAjXhuWKaEDFXvZZwmCimpO5T0faxacIHJ5HsxDq4f_g1iN2syBroi12tc92-otVeIwJWm8Poi1eA876OH4
  priority: 102
  providerName: Directory of Open Access Journals
– databaseName: Proquest Health & Medical Complete
  dbid: 7X7
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1fi9QwEA96gvgi_sXqqREEHyTctk3T1BfZFY9TuEPUg30L-ddzQdtz233wTfwKfkM_iTNpWq3CPS00E5Z2MjO_TCa_IeSpN5U0ueCsLkvLuHSeGSsFq4TPIaRo6UPnueMTcXTK366LdUy4dbGscvSJwVG71mKO_AAPxAa6s5fnXxl2jcLT1dhC4zK5gtRluPkq1-WUY1kAWi-rgW6PVwzAQzrem5HioOOLUE-UYUERoAImZ7EpUPj_76j_LZ78Kxod3iDXI4yky0HvN8kl39wiV4_jQflt8uNd6MUNcYm2NQWQR2sP2qBfNgPxUq-pbhy1m60N_btALgy9P1myVNBNQ9-sPtBuZzBN01HM1tIVAO2-td_AKXR0LOJq6AuqqYVY-Ov7z1j3TgNn7R1yevj646sjFtstMFuUWc-szXnhCssFbhqFhx8L3q-SwmdSZ2C94N2ctovCQVgr6rxMawBszldGe-tlfpfsNW3j7xHqUq4L6xegM8ld4Qx3yAyG2KbOMukSko4fWtnIRY4tMT6rsCeRQg3KUaAcFZSjZEKeT3POByaOC6VXqL9JElm0w4N2e6aiUcJc4-uyFtoLza00sihkzjMuTOph42kS8hi1r4YrqZMvUMsSIjrHBZmQZ0ECvQG8gNXxUgN8BuTVmknuzyTBiu18eFxhKnqRTv1Z8wl5Mg3jTKyMa3y7QxkpQnP7RULkbGXO3n0-0mw-BSbxNFgIF_cv_vcH5FqGZoLZdLFP9vrtzj8ELNabR8HgfgPBHzCX
  priority: 102
  providerName: ProQuest
Title Profiling of the fecal microbiota and circulating microRNA-16 in IBS subjects with Blastocystis infection : a case–control study
URI https://www.proquest.com/docview/2890106778
https://www.proquest.com/docview/2886940070
https://pubmed.ncbi.nlm.nih.gov/PMC10626746
https://doaj.org/article/11bef7f6ae6a4c8b855834246b1e140b
Volume 28
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1bi9QwFA57AfFFvGJ1HSMIPkh12qZJRhCZkV3WgRmWXQfmLeRWHVhbnQu4b4I_wT_gb_Gn-Es8J20Hq4vgU6E5KSQn55L05PsIeezNQJqMs7gQwsZMOh8bK3k84D6DkKKlD8xzkyk_nrHxPJ_vkJbuqJnA1aVbO-STmi3Pn33-dPEKDP5lMHjJn69YPxQGpVgZBOE9lrtkHyKTQCqHSZPu15455SJQSqYIUCBkNm_v0Vz6mU6sCpD-fzvuP4spf4tOR9fJtSatpMN6HdwgO768Sa5Mmh_nt8jXk8DNDXGKVgWFpI8WHrRDPyxqIKa1prp01C6WNvB5gVxoOp0O44TTRUnfjM7oamPw2GZF8fSWjiDxXlf2ApzEirZFXeWP7y-ophaC488v35pCeBpAbG-T2dHh29fHccO_ENtcpOvY2ozlLreM4y6Se3hYcIcDyX0qdQrmDO7OadvPHcS5vMhEUkAG5_zAaG-9zO6QvbIq_V1CXcJ0bn1fDvqSudwZ5hAqDJOdIk2li0jSzrSyDTg5cmScq7BJkVzV2lGgHRW0o2REnm77fKyhOf4pPUIFbiURVju8qJbvVGOl0Nf4QhRce66ZlUbmucxYyrhJPOxETUQeovpVfUd16xzUUECIZzC4JCJPggQuWBiA1c0tB5gGBNrqSB50JMGsbbe5XWKqtQqFf4VrzL-IPNo2Y08slSt9tUEZyQPbfT8isrM0O2PvtpSL9wFaPAkmwvi9_5rb--RqimaDp-38gOytlxv_AHK1temRXTEXPbI_HI7PxvAcHU5PTnvh5KMXjPMX-_Y9yQ
linkProvider Scholars Portal
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3NbtNAEF6VIgEXxK8wFLpIIA7Iamyv12skhBKgSmgTIWil3rb7Z4gEdokTod4Qr8B78FA8CTNrO2CQeuspUnY2kT3_s7PfEPLI6VzohLOwyDITMmFdqI3gYc5dAi5FCecnz01nfHzI3hylRxvkZ3cXBtsqO5voDbWtDNbId_BArIE7e3HyJcSpUXi62o3QaMRiz51-hZStfj55Bfx9HMe7rw9ejsN2qkBo0ixehsYkLLWpYRxzI-7gw4CS54K7WKgYhBSU2CozSC1Y77RIsqiAuMS6XCtnnEjgdy-Qi-B4B9hCmB1l65rOALKDLG_g_VgeQrASdfd0BN-p2cD3L8XYwARRSCh6vtCPDPjfMfzbrPmX99u9Rq62YSsdNnJ2nWy48ga5NG0P5m-S72_97G_wg7QqKASVtHDAffp53gA9LRVVpaVmvjB-XhjQ-aV3s2EYcTov6WT0ntYrjWWhmmJ1mI4gsF9W5hSMUE27prGSPqOKGvC9v779aPvsqcfIvUUOz4URt8lmWZXuDqE2Yio1bgAyIphNrWYWkcgwliriWNiARN2LlqbFPscRHJ-kz4EElw1zJDBHeuZIEZCn6z0nDfLHmdQj5N-aElG7_RfV4oNsjQDs1a7ICq4cV8wILdJUJCxmXEcOEl0dkG3kvmyuwK5tjxxmEEEwVICAPPEUaH3gAYxqL1HAa0Acrx7lVo8SrIbpL3cSJlurVcs_OhaQh-tl3ImdeKWrVkgjeM4QJSogoieZvWfvr5Tzjx65PPIawvjds_99m1weH0z35f5ktnePXIlRZbCSz7fI5nKxcvchDlzqB175KDk-b23_DVDWbUA
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Profiling+of+the+fecal+microbiota+and+circulating+microRNA-16+in+IBS+subjects+with+Blastocystis+infection%C2%A0%3A+a+case%E2%80%93control+study&rft.jtitle=European+journal+of+medical+research&rft.au=Olyaiee%2C+Alireza&rft.au=Yadegar%2C+Abbas&rft.au=Mirsamadi%2C+Elnaz+Sadat&rft.au=Sadeghi%2C+Amir&rft.date=2023-11-06&rft.issn=2047-783X&rft.eissn=2047-783X&rft.volume=28&rft.issue=1&rft_id=info:doi/10.1186%2Fs40001-023-01441-8&rft.externalDBID=n%2Fa&rft.externalDocID=10_1186_s40001_023_01441_8
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2047-783X&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2047-783X&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2047-783X&client=summon